litlas
ログインアカウント作成

David L. Porter

1987–2026 年に発表

別表記
David L Porter
101
論文数
33,091
被引用数
67
h 指数
96
i10 指数

被引用数

David L. Porter の年別被引用数1990 年: 被引用 3 件1991 年: 被引用 4 件1993 年: 被引用 2 件1994 年: 被引用 1 件1995 年: 被引用 1 件1997 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 6 件2002 年: 被引用 8 件2003 年: 被引用 12 件2004 年: 被引用 9 件2005 年: 被引用 13 件2006 年: 被引用 13 件2007 年: 被引用 14 件2008 年: 被引用 5 件2009 年: 被引用 8 件2010 年: 被引用 9 件2011 年: 被引用 37 件2012 年: 被引用 102 件2013 年: 被引用 263 件2014 年: 被引用 227 件2015 年: 被引用 439 件2016 年: 被引用 505 件2017 年: 被引用 619 件2018 年: 被引用 788 件2019 年: 被引用 1,795 件2020 年: 被引用 2,228 件2021 年: 被引用 1,882 件2022 年: 被引用 1,601 件2023 年: 被引用 1,292 件2024 年: 被引用 2,021 件2025 年: 被引用 1,154 件2026 年: 被引用 35 件1992 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません1998〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,534 件、この内訳の 33.8%中国: 引用元論文 1,713 件、この内訳の 12.8%ドイツ: 引用元論文 952 件、この内訳の 7.1%イギリス: 引用元論文 614 件、この内訳の 4.6%イタリア: 引用元論文 524 件、この内訳の 3.9%フランス: 引用元論文 481 件、この内訳の 3.6%スペイン: 引用元論文 395 件、この内訳の 3%カナダ: 引用元論文 367 件、この内訳の 2.7%オーストラリア: 引用元論文 326 件、この内訳の 2.4%スイス: 引用元論文 326 件、この内訳の 2.4%オランダ: 引用元論文 287 件、この内訳の 2.2%日本: 引用元論文 280 件、この内訳の 2.1%
0%33.8%その他 19.4%

機関

分野

  • Medicine81.9%
  • Biochemistry, Genetics and Molecular Biology8.5%
  • Immunology and Microbiology7.3%
  • Engineering1.1%
  • Materials Science0.3%
  • Neuroscience0.3%
  • その他0.6%

トピック

  • CAR-T cell therapy research24.3%
  • Immune Cell Function and Interaction7.5%
  • Virus-based gene therapy research6.5%
  • Immunotherapy and Immune Responses5.1%
  • Nanowire Synthesis and Applications4.5%
  • Cancer Immunotherapy and Biomarkers3.6%
  • その他48.5%

共著者

全論文

検索で開く
  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

    著者: Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw, Richard Aplenc, David M. Barrett, Nancy Bunin, Anne Chew, Vanessa Gonzalez, Zhaohui Zheng, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Susan R. Rheingold, Angela Shen, David T. Teachey, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - New England Journal of Medicine 2014 被引用: 5,408

  2. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    著者: Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O’Connor, Wei‐Ting Hwang, Edward Pequignot, David E Ambrose, Changfeng Zhang, Nicholas S. Wilcox, Felipe Bedoya, Corin L. Dorfmeier, Chen Fang, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. Brad Johnson, Irina Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, Megan M. Davis, Bruce L. Levine, Noelle V. Frey, Donald L. Siegel, Alexander C. Huang, E. John Wherry, Hans Bitter, Jennifer L. Brogdon, David L. Porter, Carl H. June, J. Joseph Melenhorst - Nature Medicine 2018 被引用: 1,770

  3. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

    著者: J. Joseph Melenhorst, Gregory M. Chen, Meng Wang, David L. Porter, Changya Chen, McKensie Collins, Peng Gao, Shovik Bandyopadhyay, Hongxing Sun, Ziran Zhao, Stefan Lundh, Iulian Pruteanu-Malinici, Christopher L. Nobles, Sayantan Maji, Noelle V. Frey, Saar Gill, Alison W. Loren, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, David E Ambrose, Megan M. Davis, Joseph A. Fraietta, Jennifer L. Brogdon, Regina M. Young, Anne Chew, Bruce L. Levine, Donald L. Siegel, Cécile Alanio, E. John Wherry, Frederic D. Bushman, Simon F. Lacey, Kai Tan, Carl H. June - Nature 2022 被引用: 947

  4. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    著者: David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June - New England Journal of Medicine 2011 被引用: 3,541

  5. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

    著者: Stephan A. Grupp, Michael Kalos, David M. Barrett, Richard Aplenc, David L. Porter, Susan R. Rheingold, David T. Teachey, Anne Chew, Bernd Hauck, J. Fraser Wright, Michael C. Milone, Bruce L. Levine, Carl H. June - New England Journal of Medicine 2013 被引用: 3,491

  6. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    著者: Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Sunita D. Nasta, Anthony R. Mato, Özlem Anak, Jennifer L. Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel J. Landsburg, Mariusz A. Wasik, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, David L. Porter, Carl H. June - New England Journal of Medicine 2017 被引用: 1,854

  7. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    著者: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 被引用: 256

  8. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    著者: Michael Kalos, Bruce L. Levine, David L. Porter, Sharyn I. Katz, Stephan A. Grupp, Adam Bagg, Carl H. June - Science Translational Medicine 2011 被引用: 2,403

  9. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

    著者: Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap Jan Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John A. Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel‐Angel Perales - Nature Medicine 2024 被引用: 196

  10. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

    著者: David T. Teachey, Simon F. Lacey, Pamela A. Shaw, J. Joseph Melenhorst, Shannon L. Maude, Noelle V. Frey, Edward Pequignot, Vanessa Gonzalez, Fang Chen, Jeffrey Finklestein, David M. Barrett, Scott L. Weiss, Julie C. Fitzgerald, Robert A. Berg, Richard Aplenc, Colleen Callahan, Susan R. Rheingold, Zhaohui Zheng, Stefan Rose‐John, Jason C. White, Farzana Nazimuddin, Gerald Wertheim, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - Cancer Discovery 2016 被引用: 1,084

  11. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    著者: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John Slingerland, Silvia Beghi, Pamela S. Herrera, Paul A. Giardina, Annelie Clurman, Emmanuel Agyemang Dwomoh, Gabriel K. Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schlüter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel D. Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel‐Angel Perales, Craig W. Freyer, Alfred L. Garfall, Shannon Gier, Sunita D. Nasta, Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 被引用: 309

  12. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

    著者: Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech, Charly R. Good, Shunichiro Kuramitsu, Tong Da, Mercy Gohil, Linhui Chen, Seok-Jae Albert Hong, Pranali Ravikumar, Austin K. Rennels, January Salas-McKee, Weimin Kong, Marco Ruella, Megan M. Davis, Gabriela Plesa, Joseph A. Fraietta, David L. Porter, Regina M. Young, Carl H. June - Immunity 2023 被引用: 166

  13. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

    著者: Noelle V. Frey, David L. Porter - Biology of Blood and Marrow Transplantation 2018 被引用: 386

  14. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

    著者: Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, J. Joseph Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill - Journal of Clinical Investigation 2016 被引用: 555

  15. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

    著者: Julie C. Fitzgerald, Scott L. Weiss, Shannon L. Maude, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Pamela A. Shaw, Robert A. Berg, Carl H. June, David L. Porter, Noelle V. Frey, Stephan A. Grupp, David T. Teachey - Critical Care Medicine 2016 被引用: 455

  16. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies

    著者: Craig W. Freyer, David L. Porter - Journal of Allergy and Clinical Immunology 2020 被引用: 206

  17. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

    著者: Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, J. Joseph Melenhorst, Farzana Nazimuddin, Wei‐Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen J. Schuster, Michael D. Feldman, David L. Porter, Stephen Grupp, Carl H. June, Michael C. Milone - Blood 2016 被引用: 271

  18. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

    著者: Noelle V. Frey, Pamela A. Shaw, Elizabeth O. Hexner, Edward Pequignot, Saar Gill, Selina M. Luger, James K. Mangan, Alison W. Loren, Alexander E. Perl, Shannon L. Maude, Stephan A. Grupp, Nirav N. Shah, Joan Gilmore, Simon F. Lacey, Jos Melenhorst, Bruce L. Levine, Carl H. June, David L. Porter - Journal of Clinical Oncology 2019 被引用: 269

  19. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy

    著者: Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark‐David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt - Blood 2019 被引用: 186

  20. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

    著者: Shannon L. Maude, David T. Teachey, David L. Porter, Stephan A. Grupp - Blood 2015 被引用: 720

  21. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

    著者: Guido Ghilardi, Elise A. Chong, Jakub Svoboda, Philipp Wohlfarth, Sunita D. Nasta, Staci Williamson, J.D. Landsburg, James N. Gerson, Stefan K. Barta, Raymone Pajarillo, Jessie Myers, A.I. Chen, Levanto Schachter, Rebecca Yelton, Hatcher J. Ballard, Alexandria Hodges Dwinal, Shannon Gier, Danielle Victoriano, Erin L. Weber, Ellen Napier, Alfred L. Garfall, David L. Porter, Ulrich Jäger, Richard T. Maziarz, Marco Ruella, Stephen J. Schuster - Annals of Oncology 2022 被引用: 97

  22. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

    著者: Karen Thudium Mueller, Shannon L. Maude, David L. Porter, Noelle V. Frey, Patricia A. Wood, Xia Han, Edward Waldron, Abhijit Chakraborty, Rakesh Awasthi, Bruce L. Levine, J. Joseph Melenhorst, Stephan A. Grupp, Carl H. June, Simon F. Lacey - Blood 2017 被引用: 359

  23. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

    著者: Saar Gill, Sarah K. Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. Porter, Martin Carroll, Gwenn Danet-Desnoyers, John Scholler, Stephan A. Grupp, Carl H. June, Michael Kalos - Blood 2014 被引用: 491

  24. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

    著者: Michael Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael Bishop - Journal for ImmunoTherapy of Cancer 2018 被引用: 247